# LAM Pilot Study With Imatinib Mesylate

> **NCT03131999** · PHASE1,PHASE2 · COMPLETED · sponsor: **Medical University of South Carolina** · enrollment: 18 (actual)

## Conditions studied

- Lymphangioleiomyomatosis

## Interventions

- **DRUG:** Imatinib Mesylate 400Mg Capsule
- **DRUG:** Placebo - Capsule

## Key facts

- **NCT ID:** NCT03131999
- **Lead sponsor:** Medical University of South Carolina
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-23
- **Primary completion:** 2019-03-07
- **Final completion:** 2019-03-07
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2020-06-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03131999

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03131999, "LAM Pilot Study With Imatinib Mesylate". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03131999. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*